KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Cash & Equivalents: 2020-2024

Historic Cash & Equivalents for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Dec 2024 value amounting to $594.4 million.

  • Recursion Pharmaceuticals' Cash & Equivalents rose 54.29% to $659.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $659.8 million, marking a year-over-year increase of 54.29%. This contributed to the annual value of $594.4 million for FY2024, which is 51.79% up from last year.
  • According to the latest figures from FY2024, Recursion Pharmaceuticals' Cash & Equivalents is $594.4 million, which was up 51.79% from $391.6 million recorded in FY2023.
  • In the past 5 years, Recursion Pharmaceuticals' Cash & Equivalents registered a high of $594.4 million during FY2024, and its lowest value of $262.1 million during FY2020.
  • For the 3-year period, Recursion Pharmaceuticals' Cash & Equivalents averaged around $511.9 million, with its median value being $549.9 million (2022).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 92.87% in 2022, then declined by 28.79% in 2023.
  • Recursion Pharmaceuticals' Cash & Equivalents (Yearly) stood at $262.1 million in 2020, then rose by 8.77% to $285.1 million in 2021, then spiked by 92.87% to $549.9 million in 2022, then declined by 28.79% to $391.6 million in 2023, then skyrocketed by 51.79% to $594.4 million in 2024.